WHO ICTRP trial
The efficacy, safety and mechanism of esketamine vs electroconvulsive therapy in…
ChiCTR2300071697 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300071697 |
|---|---|
| Public title | The efficacy, safety and mechanism of esketamine vs electroconvulsive therapy in the treatment of suicidal risk of patients with major depressive episode |
| Scientific title | The efficacy, safety and mechanism of esketamine vs electroconvulsive therapy in the treatment of suicidal risk of patients with major depressive episode |
| Primary sponsor | The Affiliated Brain Hospital of Guangzhou Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Major depressive episode with suicidal ideation |
| Interventions | Esketamine group:intravenous infusion of esketamine (0.5mg/kg);MECT group:MECT |
| Registration date | May 23, 2023 |
| Target size | Esketamine group:150;MECT group:150 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: